专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07361646B2 Methods for treating gastroesophageal reflux disease 有权
标题翻译：治疗胃食管反流病的方法
公开(公告)号：US07361646B2
公开(公告)日：2008-04-22
申请号：US10702950
申请日：2003-11-05
申请人： Joseph K. Belanoff
发明人： Joseph K. Belanoff
IPC分类号： A61K31/56 , A61K31/573
CPC分类号： A61K31/59 , A61K31/00 , A61K31/56 , A61K31/573
摘要： This invention relates to the discovery that agents capable of inhibiting the biological action of the glucocorticoid receptor can be used in methods for treating gastroesophageal reflux disease in a subject.
摘要翻译：本发明涉及能够抑制糖皮质激素受体的生物学作用的试剂可用于治疗受试者胃食管反流病的方法。

2. 发明授权

US07163934B2 Methods for treating delirium glucocorticoid receptor-specific antagonists 有权
标题翻译：治疗del妄糖皮质激素受体特异性拮抗剂的方法
公开(公告)号：US07163934B2
公开(公告)日：2007-01-16
申请号：US10257656
申请日：2002-05-06
申请人： Joseph K. Belanoff
发明人： Joseph K. Belanoff
IPC分类号： A61K31/56
CPC分类号： A61K31/47 , A61K31/573
摘要： This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for treating delirium. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for treating delirium in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.
摘要翻译：本发明一般涉及精神病学领域。特别地，本发明涉及抑制皮质醇与其受体结合的药剂可用于治疗del妄的方法。米非司酮是一种有效的特异性糖皮质激素受体拮抗剂，可用于这些方法。本发明还提供了一种用于治疗人类del妄的试剂盒，其包括糖皮质激素受体拮抗剂和教导糖皮质激素受体拮抗剂施用的适应症，剂量和时间表的教学材料。

3. 发明授权

US06680310B2 Methods for preventing antipsychotic-induced weight gain 有权
标题翻译：预防抗精神病药物引起体重增加的方法
公开(公告)号：US06680310B2
公开(公告)日：2004-01-20
申请号：US10201356
申请日：2002-07-22
申请人： Joseph K. Belanoff , Alan F. Schatzberg
发明人： Joseph K. Belanoff , Alan F. Schatzberg
IPC分类号： A61K3156
CPC分类号： A61K45/06 , A61K31/00 , A61K31/5513 , A61K31/567 , A61K31/575 , A61K2300/00
摘要： This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptors can be used in methods for preventing antipsychotic-induced weight gain. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for preventing AP-induced weight gain in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.
摘要翻译：本发明一般涉及精神病学领域。特别地，本发明涉及能够抑制皮质醇与其受体的结合的试剂可用于预防抗精神病药引起的体重增加的方法。米非司酮是一种有效的特异性糖皮质激素受体拮抗剂，可用于这些方法。本发明还提供了一种用于预防包括糖皮质激素受体拮抗剂在内的人类AP诱导的体重增加的试剂盒，以及教导糖皮质激素受体拮抗剂施用的适应症，剂量和时间表的教学材料。

4. 发明授权

US06620802B1 Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist 有权
标题翻译：使用糖皮质激素特异性受体拮抗剂治疗轻度认知障碍的方法
公开(公告)号：US06620802B1
公开(公告)日：2003-09-16
申请号：US09717703
申请日：2000-11-20
申请人： Alan F. Schatzberg , Joseph K. Belanoff
发明人： Alan F. Schatzberg , Joseph K. Belanoff
IPC分类号： A61K3156
CPC分类号： A61K31/568 , A61K31/00 , A61K31/56 , A61K31/567
摘要： This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for treating mild cognitive impairment. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for treating mild cognitive impairment in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.
摘要翻译：本发明一般涉及精神病学领域。特别地，本发明涉及抑制皮质醇与其受体结合的药剂可用于治疗轻度认知障碍的方法。米非司酮是一种有效的特异性糖皮质激素受体拮抗剂，可用于这些方法。本发明还提供了一种用于治疗人类轻度认知障碍的试剂盒，其包括糖皮质激素受体拮抗剂和教导糖皮质激素受体拮抗剂施用的适应症，剂量和时间表的教学材料。

5. 发明授权

US08097606B2 Antiglucocorticoids for the treatment of catatonia 有权
标题翻译：用于治疗紧张症的抗糖皮质激素
公开(公告)号：US08097606B2
公开(公告)日：2012-01-17
申请号：US10896143
申请日：2004-07-20
申请人： Joseph K. Belanoff
发明人： Joseph K. Belanoff
IPC分类号： A61K31/56
CPC分类号： A61K31/56 , A61K31/00 , A61K31/05 , A61K31/567 , A61K31/568 , A61K31/58
摘要： The invention provides a method of ameliorating the symptoms of catatonia in a patient who is in need of treatment for catatonia. The method comprises administration of a therapeutically effective amount of a glucocorticoid receptor antagonist to the patient.
摘要翻译：本发明提供了一种改善需要治疗紧张症的病人的紧张症症状的方法。该方法包括向患者施用治疗有效量的糖皮质激素受体拮抗剂。

6. 发明申请

US20090062248A1 OPTIMIZING MIFEPRISTONE LEVELS IN PLASMA SERUM OF PATIENTS SUFFERING FROM MENTAL DISORDERS TREATABLE WITH GLUCOCORTICOID RECEPTOR ANTAGONISTS 有权
标题翻译：优于使用葡萄糖激素受体拮抗剂治疗的精神障碍患者血浆中的MIFEPRISTONE水平
公开(公告)号：US20090062248A1
公开(公告)日：2009-03-05
申请号：US12199114
申请日：2008-08-27
申请人： Joseph K. Belanoff
发明人： Joseph K. Belanoff
IPC分类号： A61K31/56 , A61P25/00
CPC分类号： G01N33/49 , A61K31/56 , A61K31/567 , A61K31/575
摘要： The present invention provides a method for optimizing levels of mifepristone in a patient suffering from a mental disorder amenable to treatment by mifepristone. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1300 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1300 ng/mL.
摘要翻译：本发明提供了一种优化米非司酮治疗患有精神障碍患者的米非司酮水平的方法，该方法适用于米非司酮治疗。该方法包括以下步骤：在七天或更多天的时间内用七日或更多日剂量的米非司酮治疗患者; 测试患者的血清水平以确定米非司酮的血液水平是否大于1300ng / mL; 并调整患者的日剂量以达到大于1300ng / mL的米非司酮血药浓度。

7. 发明授权

US08450379B2 Methods for treating migraine 有权
标题翻译：偏头痛治疗方法
公开(公告)号：US08450379B2
公开(公告)日：2013-05-28
申请号：US10703069
申请日：2003-11-05
申请人： Joseph K. Belanoff
发明人： Joseph K. Belanoff
IPC分类号： A61K31/045 , A61K31/05
CPC分类号： A61K31/59 , A61K31/00 , A61K31/56 , A61K31/573
摘要： This invention relates to the discovery that agents capable of inhibiting the biological action of the glucocorticoid receptor can be used in methods for treating migraine in a subject.
摘要翻译：本发明涉及能够抑制糖皮质激素受体的生物学作用的药剂可用于治疗受试者偏头痛的方法。

8. 发明申请

US20090029959A1 Antiglucocorticoid Therapy for the Prevention of Neurological Damage in Premature Infants 审中-公开
标题翻译：用于预防早产儿神经损伤的抗糖皮质激素治疗
公开(公告)号：US20090029959A1
公开(公告)日：2009-01-29
申请号：US12238751
申请日：2008-09-26
申请人： Joseph K. Belanoff
发明人： Joseph K. Belanoff
IPC分类号： A61K31/573 , A61P25/00
CPC分类号： A61K31/56 , A61K31/567 , A61K31/569 , A61K31/573 , A61K45/06 , A61K2300/00
摘要： This invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for preventing neurological damage associated with glucocorticoid therapy in ventilator-dependent low birth weight preterm infants. Mifepristone, a potent glucocorticoid receptor antagonist, can be used in these methods.
摘要翻译：本发明涉及以下发现：抑制皮质醇与其受体结合的药剂可以用于预防与通气机相关的低出生体重早产儿中糖皮质激素治疗相关的神经损伤的方法。米非司酮是一种有效的糖皮质激素受体拮抗剂，可用于这些方法。

9. 发明授权

US07402578B2 Methods for inhibiting cognitive deterioration in adults with down's syndrome 有权
标题翻译：抑郁症综合征成人认知功能衰退的方法
公开(公告)号：US07402578B2
公开(公告)日：2008-07-22
申请号：US10230575
申请日：2002-08-28
申请人： Joseph K. Belanoff
发明人： Joseph K. Belanoff
IPC分类号： A61K31/56
CPC分类号： A61K31/573 , A61K31/56 , A61K31/567 , A61K31/575
摘要： This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptors can be used in methods for preventing or reversing cognitive deterioration in adults with Down's syndrome. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for preventing or reversing cognitive deterioration in a DS patient including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.
摘要翻译：本发明一般涉及精神病学领域。特别地，本发明涉及以下发现：能够抑制皮质醇与其受体结合的药剂可用于预防或逆转唐氏综合症患者的认知衰退的方法。米非司酮是一种有效的特异性糖皮质激素受体拮抗剂，可用于这些方法。本发明还提供了用于预防或逆转DS患者的认知恶化的试剂盒，其包括糖皮质激素受体拮抗剂和教导糖皮质激素受体拮抗剂施用的适应症，剂量和时间表的说明材料。

10. 发明授权

US06362173B1 Methods for treating psychosis associated with cocaine addiction with glucocorticoid receptor antagonists 有权
标题翻译：用糖皮质激素受体拮抗剂治疗与可卡因成瘾有关的精神病的方法
公开(公告)号：US06362173B1
公开(公告)日：2002-03-26
申请号：US09639377
申请日：2000-08-15
申请人： Alan F. Schatzberg , Joseph K. Belanoff
发明人： Alan F. Schatzberg , Joseph K. Belanoff
IPC分类号： A61K3156
CPC分类号： A61K31/57 , A61K31/00 , A61K31/567 , A61K31/569 , A61K31/575
摘要： This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for ameliorating pathologies or conditions associated with psychosis. These pathologies or conditions include psychotic major depression, schizoaffective disorders, Alzheimer's Disease and cocaine addiction. Mifepristone, a potent glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for the amelioration of psychosis in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.
摘要翻译：本发明一般涉及精神病学领域。特别地，本发明涉及抑制皮质醇与其受体结合的药剂可用于改善与精神病有关的病状或病症的方法。这些病理或病症包括精神病性重症抑郁症，分裂情感障碍，阿尔茨海默病和可卡因成瘾。米非司酮是一种有效的糖皮质激素受体拮抗剂，可用于这些方法。本发明还提供了用于改善人类精神病的试剂盒，包括糖皮质激素受体拮抗剂和教导糖皮质激素受体拮抗剂施用的适应症，剂量和时间表的教学材料。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式